Form 4: Neurogene Director Rohan Palekar Granted 12,050 Stock Options

Neurogene Inc. Director Rohan Palekar was granted 12,050 non-qualified stock options with an exercise price of $20.40, vesting monthly over one year.

Summary

• Rohan Palekar, a Director of Neurogene Inc. (NGNE), was granted 12,050 non-qualified stock options.
• The options have an exercise price of $20.40 per share.
• The grant date for these options was June 12, 2025.
• The options will vest monthly, with 1/12 of the total shares vesting each month, starting July 12, 2025.
• Full vesting is expected by June 12, 2026, contingent on Mr. Palekar's continued service to Neurogene Inc.
• The options have an expiration date of June 12, 2035.
• Following this transaction, Mr. Palekar directly beneficially owns 12,050 derivative securities.
• The filing was made by Donna M. Cochener, acting as attorney-in-fact for Rohan Palekar, under a Power of Attorney dated June 12, 2025.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive sign, indicating alignment of interests and retention efforts. It's a routine compensation event, not indicative of major positive or negative news, hence a neutral-to-slightly positive score.

Positives

• The grant of stock options aligns the director's interests with long-term shareholder value.
• The vesting schedule encourages continued service and commitment from the director.

Risks

• Vesting of the options is subject to Rohan Palekar's continued provision of service to Neurogene Inc. on each vesting date.

Future Outlook

The vesting schedule for the granted options extends until June 12, 2026, indicating a future commitment period for the director's service.

Industry Context

This is a routine insider transaction filing (Form 4) reporting the grant of stock options to a director, a common practice in the biotechnology or pharmaceutical industry (Neurogene Inc.) to incentivize and retain key personnel. Such grants align management interests with long-term shareholder value, a standard corporate governance practice across industries.

Comparison to Industry Standards

• The grant of non-qualified stock options to a director is a standard form of equity compensation across publicly traded companies, particularly in the biotechnology sector where long-term incentives are crucial for retaining talent and aligning interests with the company's development cycles.
• The vesting schedule over one year is a common practice, though longer vesting periods (e.g., 3-4 years) are also prevalent for executive grants.
• Specific comparable companies or projects are not detailed in this filing, as it focuses solely on an individual's transaction.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution upon exercise of options, but also potential benefit from aligned director interests and retention.

Next Steps

• Continued service by Rohan Palekar to Neurogene Inc. for the options to fully vest by June 12, 2026.
• Potential future exercise of options by Rohan Palekar before the expiration date of June 12, 2035.

Key Dates

Recommendation

Keywords

Neurogene Inc., NGNE, Rohan Palekar, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Vesting Schedule